MyoHtutMD

PubMed

• Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for Hi...
  Colton Ladbury, James Sanchez, Arnab Chowdhury, Joycelynne Palmer, An Liu, Anthony Stein, Myo Htut, Leonardo Farol, Ji-Lian Cai, George Somlo, Michael Rosenzweig, Jeff...> ;American Journal of Clinical Oncology. 2024 Mar 14
• Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
  Kumar, S., Callander, N., Adekola, K., Anderson, L., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J., Costello, C., D'Angelo, C., Derman, B., Devarakonda, S., Else...> ;Journal of the National Comprehensive Cancer Network. 2024 Jan 1
• 1 citations
  Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
  Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christoph...> ;Journal of the National Comprehensive Cancer Network. 2023 Dec 1
• 3 citations
  Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
  Surbhi Sidana, Hitomi Hosoya, Alexandria Jensen, Lawrence Liu, Anmol Goyal, Vanna Hovanky, Bita Sahaf, Sushma Bharadwaj, Theresa Latchford, Sally Arai, Sheryl Leahy, M...> ;Blood Cancer Journal. 2023 Oct 13
• 5 citations
  Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-c...
  Shin Yeu Ong, Stacy Pak, Matthew Mei, Yan Wang, Leslie Popplewell, John H Baird, Alex F Herrera, Geoffrey Shouse, Liana Nikolaenko, Jasmine Zain, James Godfrey, Myo Ht...> ;American Journal of Hematology. 2023 Nov 1
• 2 citations
  Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
  Myo Htut, Binod Dhakal, Adam D Cohen, Thomas Martin, Jesus G Berdeja, Saad Z Usmani, Mounzer Agha, Carolyn C Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Dec 1
• Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation UsingY-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan i...
  Matthew Mei, Joycelynne Palmer, Nicole Ni-Chun Tsai, Jennifer Simpson, James O'Hearn, Anthony Stein, Stephen Forman, Ricardo Spielberger, Ji-Lian Cai, Myo Htut, Ryotar...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
• 7 citations
  Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
  Sham Mailankody, Jeffrey V Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, My...> ;Nature Medicine. 2023 Dec 1
• 58 citations
  Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
  Sham Mailankody, Jeffrey V Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, My...> ;Nature Medicine. 2023 Feb 1
• 15 citations
  Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.
  Taxiarchis Kourelis, Radhika Bansal, Jesus Berdeja, David Siegel, Krina Patel, Sham Mailankody, Myo Htut, Nina Shah, Sandy W Wong, Surbhi Sidana, Andrew J Cowan, Melis...> ;Transplantation and Cellular Therapy. 2023 Apr 1
• 5 citations
  Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
  Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christopher D'Angelo,...> ;Journal of the National Comprehensive Cancer Network. 2023 Jan 1
• 3 citations
  Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the ...
  Adam D Cohen, Parameswaran Hari, Myo Htut, Jesus G Berdeja, Saad Z Usmani, Deepu Madduri, Yunsi Olyslager, Jenna D Goldberg, Jordan M Schecter, Carolyn C Jackson, Kath...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jan 1
• 10 citations
  Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
  Thomas Martin, Yi Lin, Mounzer Agha, Adam D Cohen, Myo Htut, A Keith Stewart, Parameswaran Hari, Jesus G Berdeja, Saad Z Usmani, Tzu-Min Yeh, Yunsi Olyslager, Jenna D ...> ;The Lancet. Haematology. 2022 Dec 1
• 8 citations
  Interferon-γ blockade in CAR T-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis.
  Michael Rainone, Dat Ngo, John H Baird, L Elizabeth Budde, Myo Htut, Ibrahim Aldoss, Vinod Pullarkat> ;Blood Advances. 2023 Feb 28
• 139 citations
  Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...
  Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C Munshi...> ;Journal of Clinical Oncology. 2023 Feb 20
• 70 citations
  NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
  Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, Larry D Anderson, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, M...> ;Journal of the National Comprehensive Cancer Network. 2022 Jan 1
• 4 citations
  Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
  Jonathan L Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder, Jeffrey A Zonder, Joseph W Fay, Manuel R Modiano, Erin L Moshier, Selena A Rush, Brian J Tunquist, Aja...> ;Cancer Medicine. 2022 Jan 1
• 7 citations
  A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
  Karthik Ramasamy, Ajay K. Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A. Tuchman, Jacob P. Laubach, Cristina Gasparetto, Asher Chanan-Khan, Mar...> ;Blood Cancer Journal. 2021 Sep 3
• 528 citations
  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CART...
  Jesus G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, A. Keith Stewart, Parameswaran Hari, Myo Htut, Alexander M. Lesokhin,...> ;Lancet. 2021 Jul 24
• 48 citations
  Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
  Domenico Viola, Ada Dona, Enrico Caserta, Estelle Troadec, Francesca Besi, Tinisha McDonald, Lucy Ghoda, Emine Gulsen Gunes, James F. Sanchez, Jihane Khalife, Marianna...> ;Leukemia. 2021 Jan 1
• 151 citations
  Multiple myeloma, version 3.2021
  Shaji Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljevic, Erica L. Campagnaro, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Y...> ;Journal of the National Comprehensive Cancer Network. 2020 Dec 2
• 6 citations
  Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma
  Nitya Nathwani, Joycelynne Palmer, Timothy W. Synold, Behrouz Salehian, Michael Rosenzweig, James F. Sanchez, Samantha N. Hammond, Kehinde Adekola, Valeria Tomarchio, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 May 29
• 12 citations
  Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study.
  Michael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, Tim Synold, Xiwei Wu, Shu Tao, Samantha N. Hammond, Ralf Buettner, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya...> ;Leukemia & Lymphoma. 2020 Apr 8
• 156 citations
  Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
  Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson, Anupkumar George, Hartmut Goldschmidt, Alessandra Larocca, Asher Chanan-Khan,...> ;The Lancet. Haematology. 2019 Jul 18
• Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
  Myo Htut> ;Current Hematologic Malignancy Reports. 2019 Feb 1
• Join now to see all

Journal Articles

• Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma  
  Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology

Abstracts/Posters

• Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  Myo Htut, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• CD84: A Potential Novel Therapeutic Target in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018